GID-HTE10039 Drug-eluting stents for treating coronary artery disease: Supplementary file 1.



Figure 1: Study selection flowchart for clinical evidence.

Table 1: Studies excluded at pragmatic screening stage.

#	Reference	Year	Title	Reason for exclusion
1	L. N. Andreasen; I. R. Balleby; T. O. Barkholt; L. Hebsgaard; C. J. Terkelsen; E. N. Holck; L. O. Jensen; M. Maeng; J. Dijkstra; L. Antonsen; et al.	2023	Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: the SORT-OUT VIII OCT study	Less than 1 year follow-up.
2	L. N. Andreasen; I. R. Balleby; T. Ø. Barkholt; L. Hebsgaard; C. J. Terkelsen; E. N. Holck; L. O. Jensen; M. Maeng; J. Dijkstra; L. Antonsen; S. D. Kristensen; S. Tu; J. F. Lassen; E. H. Christiansen; N. R. Holm	2023	Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT-OUT VIII OCT study	Duplicate.
3	L. N. Andreasen; N. R. Holm; I. R. Balleby; L. R. Krusell; M. Maeng; L. Jakobsen; K. T. V. Veien; K. N. Hansen; S. D. Kristensen; A. Kaltoft; J. Dijkstra; J. Hjort; S. Tu; C. J. Terkelsen; J. F. Lassen; M. Madsen; H. E. Botker; L. O. Jensen; E. H. Christiansen	2016	Randomised comparison of sirolimus-eluting and biolimus-eluting bioresorbable polymer stents: The SORT-OUT VII OCT study	Comparator not in scope.
4	Anonymous	2011	BioMime - A sirolimus-eluting coronary stent system for the treatment of patients with De Novo Coronary Lesions - meriT-1 report	Duplicated data reported elsewhere.
5	U. Baber; R. Chandiramani; S. R. Mehta; S. Sartori; Z. Zhang; B. E. Claessen; C. Briguori; S. Sharma; G. Dangas; R. Mehran	2021	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY	Intervention and comparator of original RCT not in scope. Pre-specified analysis comparing DES but trial not stratified by DES type so excluded.
6	A. Baumbach; A. J. Lansky; Y. Onuma; T. Asano; T. Johnson; R. Anderson; F. Kiemeneij; M. Zheng; N. Van Royen; T. Slagboom; et al.	2018	Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers	Less than 1 year follow-up.
7	C. Bernelli; A. Chieffo; G. L. Buchanan; M. Montorfano; M. Carlino; A. Latib; F. Figini; K. Takagi; T. Naganuma; D. MacCagni; A. Colombo	2013	New-generation drug-eluting stent experience in the percutaneous treatment of unprotected left main coronary artery disease: The NEST registry	Out of scope stents included and results not reported per individual stent.
8	G. Bouras; S. Jhamnani; V. G. Ng; I. Haimi; V. Mao; R. Deible; S. Cao; K. Sudhir; A. J. Lansky	2017	Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials	Subgroup not in scope.
9	C. Briguori; G. Visconti; M. Donahue; V. Di Palma; F. De Micco; G. Signoriello; A. Focaccio	2016	Performance of the XLIMUS Sirolimus-Eluting Coronary Stent in Very Complex Lesions	Duplicate.

#	Reference	Year	Title	Reason for exclusion
10	R. A. Buiten; E. H. Ploumen; P. Zocca; C. J. M. Doggen; L. C. van der Heijden; M. M. Kok; P. W. Danse; C. E. Schotborgh; M. Scholte; F. H. A. F. de Man; G. C. M. Linssen; C. von Birgelen	2019	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial	Out of scope subgroup of included RCT.
11	R. A. Buiten; E. H. Ploumen; P. Zocca; C. J. M. Doggen; K. G. van Houwelingen; P. W. Danse; C. E. Schotborgh; M. G. Stoel; M. Scholte; G. C. M. Linssen; F. H. A. F. de Man; C. von Birgelen	2020	Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial	Out of scope subgroup of included RCT.
12	F. Burzotta; C. Aurigemma; L. Paraggio; E. Romagnoli; A. M. Leone; R. Vergallo; S. Cangemi; F. Bianchini; C. Trani	2023	Under-deployment of extra-large drug-eluting stent: an adapted provisional technique for selected patients with distal lesions in large left main	Incorrect study design.
13	P. Chandwani; P. Verma; S. Saxena; P. K. Ramachandran; A. Abhyankar; M. S. Sandhu; N. Parikh; A. Bhupali; S. Jain; J. Prajapati	2016	Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population	Comparison made not in scope (single vessel versus multivessel PCI).
14	G. Chatzantonis; G. Chatzantonis; H. Findeisen; M. Paul; A. Samol; T. Bisdas; D. Fischer	2021	Real-world analysis of a Biolimus A9 polymer-free drug-coated stent with very short dual antiplatelet therapy in patients at high bleeding risk	Less than 1 year follow-up.
15	B. Chevalier; P. C. Smits; D. Carrie; J. Mehilli; A. J. Van Boven; E. Regar; F. J. Sawaya; D. Chamie; A. O. Kraaijeveld; T. Hovasse; G. J. Vlachojannis	2017	Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months)	Less than 1 year follow-up.
16	M. Chiarito; M. Sturla; C. Briguori; M. Mancone; C. Tamburino; F. Fabbiocchi; D. Trabattoni; F. Tomai; A. Paggi; G. Gioffre; R. Sclafani; A. Giordano; G. G. Stefanini; G. Sardella	2022	Polymer-free biolimus-A9-eluting stent performance according to renal impairment: insights from the RUDI-FREE registry	Subgroup population not in scope.
17	S. C. Cho; M. H. Jeong; W. Kim; Y. Ahn; Y. J. Hong; Y. J. Kim; C. J. Kim; M. C. Cho; K. R. Han; H. S. Kim	2014	Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease	Devices out of scope.

#	Reference	Year	Title	Reason for exclusion
18	M. Cimci; J. Polad; M. Mamas; A. Iniguez-Romo; B. Chevalier; R. Abhaichand; A. Aminian; A. Roguin; G. Maluenda; M. Angioi; G. Cassel; S. Kuramitsu; L. Jacobs; R. Debrus; F. Malik; D. Hildick-Smith; P. Laanmets; M. Roffi	2022	Outcomes and regional differences in practice in a worldwide coronary stent registry	Objective/outcomes of study not relevant to decision problem.
19	C. R. F. Costantini; M. A. Denk; S. G. Tarbine; C. C. Ortiz; V. S. Ferrari; R. M. de Macedo	2024	One-year outcomes with the Firehawk sirolimus-eluting stent and biodegradable polymer guided by intravascular ultrasound	Letter.
20	K. Dan; H. M. Garcia-Garcia; P. Kolm; S. Windecker; S. Saito; D. E. Kandzari; R. Waksman	2020	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions	Relevant primary trials already considered for inclusion separately.
21	J. M. de la Torre Hernandez; I. Otaegui; A. Subinas; A. Gomez-Menchero; R. Moreno; J. Rondan; E. Munoz-Garcia; F. Sainz-Laso; B. Garcia del Blanco; J. R. Rumoroso; J. F. Diaz; A. Berenguer; J. Gomez-Lara; J. Zueco	2021	First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study	Less than 1 year follow-up.
22	A. P. de Prado; R. Ocaranza-Sánchez; F. L. Ruiz-Poveda; J. M. Burgos; R. Á. Ramos; A. Rodrigues; L. F. González; P. Aguar; B. G. del Blanco; E. Pinar	2021	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02–RANGO study	Duplicate.
23	F. R. Eberli; H.-P. Stoll; P. Urban; M.-C. Morice; P. Brunel; L. Maillard; J. Lipiecki; S. Cook; J. Berland; T. Hovasse; D. Carrie; D. Schütte; S. S. Slama; P. Garot	2022	Polymer-free Biolimus-A9 coated thin strut stents for patients at high bleeding risk 1-year results from the LEADERS FREE III study	Longer term data available.
24	J. Fajadet; E. J. Garcia; D. Hildick-Smith; F. J. Neumann; A. S. Petronio; M. S. Spence; J. Wohrle; A. Zaman; S. Elhadad; S. Silber	2013	Results of the primary endpoint of the platinum plus trial: A prospective, randomized, multi-center trial to assess the everolimus-eluting coronary stent system (promus element) for coronary revascularization in a population of unrestricted patients	Abstract (does not meet criteria for inclusion).
25	S. Ferrarello; C. Costopoulos; A. Latib; T. Naganuma; A. Sticchi; F. Figini; S. Basavarajaiah; M. Carlino; A. Chieffo; M. Montorfano; M. Kawaguchi; C. Naim; F. Giannini; A. Colombo	2013	The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations	Out of scope intervention.
26	W. Fujimoto; T. Sawada; T. Toba; Y. Takahashi; T. Miyata; S. Oishi; T. Osue; T. Onishi; T. Takaya; A. Shimane; Y. Taniguchi; H. Kawai; Y. Yasaka	2018	Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
27	R.-L. Gao; B. Xu; A. J. Lansky; Y.-J. Yang; C.-S. Ma; Y.-L. Han; S.-L. Chen; H. Li; R.-Y. Zhang; G.-S. Fu; Z.-Y. Yuan; H. Jiang; Y. Huo; W. Li; Y.-J. Zhang; M. B. Leon	2013	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial	Less than 1 year follow-up.
28	A. Gautier; M. Roffi; P. Laanmets; S. Munir; F. T. Malik; A. I. Romo; G. Maluenda; S. Kuramitsu; M. Angioi; W. Wijns; S. Saito; B. Chevalier	2023	Complementary evidence on the performance of coronary stents generated by a randomized controlled trial and a worldwide registry	Objective/outcomes of study not relevant to decision problem.
29	A. Gautier; M. Roffi; P. Laanmets; S. Munir; F. T.-N. Malik; A. I. Romo; G. Maluenda; S. Kuramitsu; M. Angioi; W. Wijns; S. Saito; B. Chevalier	2023	Complementary evidence on the performance of coronary stents generated by a randomized controlled trial and a worldwide registry	Duplicate.
30	J. Gomez-Lara; J. H. Heo; S. Brugaletta; S. Garg; H. M. Garcia-Garcia; R. J. van Geuns; S. Silber; S. Windecker; P. W. Serruys	2011	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents	Objective/outcomes of study not relevant to decision problem.
31	J. L. Gutiérrez-Chico; R. J. van Geuns; E. Regar; W. J. van der Giessen; H. Kelbæk; K. Saunamäki; J. Escaned; N. Gonzalo; C. di Mario; F. Borgia; E. Nüesch; H. M. García-García; S. Silber; S. Windecker; P. W. Serruys	2011	Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial	Does not report key clinical outcomes.
32	Y. Hamanaka; Y. Sotomi; T. Kobayashi; T. Omatsu; J. Dijkstra; Y. Sakata; A. Hirayama; A. Hirata; Y. Higuchi	2021	Comparable neointimal healing in patients with stable coronary lesions and acute coronary syndrome: 3-month optical coherence tomography analysis	Less than 1 year follow-up.
33	M. Hamon; R. Niculescu; D. Deleanu; M. Dorobantu; N. J. Weissman; R. Waksman	2013	Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study	Less than 1 year follow-up.
34	J.-K. Han; D. Hwang; S. Yang; S.-H. Park; J. Kang; H.-M. Yang; K. W. Park; H.-J. Kang; B.-K. Koo; S.-H. Hur; W. Kim; S. Y. Kim; S.-H. Park; S. H. Han; S.-H. Kim; S. Shin; Y. H. Kim; K. Park; N. Lee; S. J. Lee; J. W. Kim; H.-S. Kim	2023	Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial	Duplicate.
35	K. N. Hansen; M. Maeng; L. Antonsen; A. Maehara; L. Jakobsen; J. Ellert; C. J. Terkelsen; O. Ahlehoff; T. Thim; C. O. Fallesen; M. Noori; K. T. Veien; L. O. Jensen; E. H. Christiansen	2022	Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
36	Y. He; R. Wang; J. Liu; F. Li; J. Li; C. Li; J. Zhou; Z. Zhao; W. Yang; F. Mou; J. Wang; J. Kan; X. Li; Y. Li; M. Zheng; S. Chen; C. Gao; L. Tao	2022	A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study	Less than 1 year follow-up.
37	R. Hemetsberger; M. Abdelghani; R. Toelg; H. M. Garcia-Garcia; S. Farhan; N. Mankerious; K. Elbasha; A. Allali; S. Windecker; T. Lefèvre; S. Saito; D. Kandzari; R. Waksman; G. Richardt	2022	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials	Relevant primary trials already considered for inclusion separately.
38	R. Hemetsberger; N. Mankerious; R. Toelg; M. Abdelghani; S. Farhan; H. M. Garcia-Garica; A. Allali; S. Windecker; T. Lefèvre; S. Saito; D. Kandzari; R. Waksman; G. Richardt	2023	Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials	Relevant primary trials already considered for inclusion separately.
39	H. Hioki; K. Kozuma; Y. Kinoshita; M. Nanasato; Y. Ito; J. Yamaguchi; N. Shiode; K. Hibi; K. Tanabe; J. Ako; Y. Morino; A. Hirohata; S. Sonoda; Y. Nakagawa; H. Okada; T. Nakagami; I. Takamisawa; K. Ando; M. Abe; Y. Ikari	2021	Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study	Objective/outcomes of study not relevant to decision problem.
40	S.-H. Hur; I.-C. Kim; K.-B. Won; Y.-K. Cho; H.-J. Yoon; C.-W. Nam; K.-B. Kim; M.-S. Kim; J. Park; S.-W. Rha; S.-C. Chae; Y.-J. Kim; C.-J. Kim; M.-C. Cho; M.-H. Jeong; Y.-K. Ahn; H.-S. Kim; T.-H. Ahn; K.-B. Seung; Y. Jang; J.-H. Yoon; I.-W. Seong; T.-J. Hong; J.-H. Bae; S.-J. Park; K. I. for the	2016	Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)	Includes out of scope stents and results not reported per stent.
41	J. F. Iglesias; D. Heg; M. Roffi; S. Degrauwe; D. Tüller; O. Muller; M. Brinkert; S. Cook; D. Weilenmann; C. Kaiser; F. Cuculi; M. Valgimigli; P. Jüni; S. Windecker; T. Pilgrim	2022	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial	Out of scope subgroup of included RCT.
42	J. F. Iglesias; D. Heg; M. Roffi; D. Tüller; S. Noble; O. Muller; I. Moarof; S. Cook; D. Weilenmann; C. Kaiser; F. Cuculi; J. Häner; P. Jüni; S. Windecker; T. Pilgrim	2019	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention	Not a key subgroup in scope.

#	Reference	Year	Title	Reason for exclusion
43	J. F. Iglesias; O. Muller; S. Losdat; M. Roffi; D. J. Kurz; D. Weilenmann; C. Kaiser; D. Heg; M. Valgimigli; S. Windecker; T. Pilgrim	2021	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial	Out of scope subgroup of included RCT.
44	J. F. Iglesias; M. Roffi; S. Losdat; O. Muller; S. Degrauwe; D. J. Kurz; L. Haegeli; D. Weilenmann; C. Kaiser; M. Tapponnier; S. Cook; F. Cuculi; D. Heg; S. Windecker; T. Pilgrim	2023	Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial	Duplicate.
45	A. Iniguez; B. Chevalier; G. Richardt; A. Neylon; V. A. Jimenez; R. Kornowski; D. Carrie; R. Moreno; E. Barbato; A. Serra-Penaranda; V. Guiducci; M. Valdes-Chavarri; J. Yajima; W. Wijns; S. Saito	2020	Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial	Out of scope subgroup of included RCT.
46	M. Ishida; R. Shimada; F. Takahashi; M. Niiyama; T. Ishisone; Y. Matsumoto; Y. Taguchi; T. Osaki; O. Nishiyama; H. Endo; R. Sakamoto; K. Tanaka; Y. Koeda; T. Kimura; I. Goto; R. Ninomiya; W. Sasaki; T. Itoh; Y. Morino	2024	One-Month Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation - The REIWA Region-Wide Registry	Objective/outcomes of study not relevant to decision problem.
47	M. Ishida; F. Takahashi; I. Goto; M. Niiyama; H. Saitoh; T. Sakamoto; Y. Maegawa; T. Osaki; O. Nishiyama; H. Endo; R. Sakamoto; T. Kojima; Y. Koeda; T. Kimura; T. Itoh; Y. Morino	2020	Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry	Objective/outcomes of study not relevant to decision problem.
48	T. Ishihara; T. Tsujimura; S. Okuno; O. Iida; M. Asai; M. Masuda; S. Okamoto; K. Nanto; T. Kanda; Y. Matsuda; T. Mano	2019	Early- and middle-phase arterial repair following bioresorbable- and durable-polymer drug-eluting stent implantation: An angioscopic study	Objective/outcomes of study not relevant to decision problem.
49	T. Itoh; H. Otake; T. Kimura; Y. Tsukiyama; T. Kikuchi; M. Okubo; T. Hayashi; T. Okamura; S. Kuramitsu; T. Morita; S. Sonoda; S. Ishihara; N. Kuriyama; T. Isshiki; T. Soeda; K. Hibi; T. Shinke; Y. Morino	2022	A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study	Objective/outcomes of study not relevant to decision problem.
50	M. Jakl; P. Cervinka; J. Kanovsky; P. Kala; M. Poloczek; M. Cervinkova; H. G. Bezerra; Z. Valenta; M. A. Costa	2023	Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
51	H.-L. Jen; Y.-C. Wang; T.-P. Tsao; W.-H. Yin	2021	Percutaneous Coronary Intervention for Very Small Vessels With the Use of a Newer-Generation 2.0 mm Drug-Eluting Stent	Objective/outcomes of study not relevant to decision problem.
52	O. Jensen Lisette; M. Maeng; B. Raungaard; J. Kahlert; J. Ellert; L. Jakobsen; A. B. Villadsen; K. T. Veien; S. D. Kristensen; O. Ahlehoff; S. Carstensen; M. K. Christensen; C. J. Terkelsen; T. Engstroem; K. N. Hansen; H. E. Bøtker; J. Aaroe; T. Thim; L. Thuesen; P. Freeman; A. Aziz; A. Eftekhari; A. Junker; S. E. Jensen; J. F. Lassen; H. S. Hansen; E. H. Christiansen	2020	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial	Duplicate.
53	V. A. Jimenez; A. Iniguez; J. A. Baz; M. Valdes; A. Ortiz; A. Vuilliomenet; V. Mainar; D. Dudek; S. Banai; D. Tuller; J.-L. Bonnet; A. De Miguel; G. Bastos; W. Wijns; S. Saito	2016	A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy	Out of scope subgroup of included RCT.
54	V. A. Jiménez; A. Iñiguez; J. A. Baz; M. Valdés; A. Ortiz; A. Vuilliomenet; V. Mainar; D. Dudek; S. Banai; D. Tüller; J. L. Bonnet; A. De Miguel; G. Bastos; W. Wijns; S. Saito	2016	A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy	Duplicate.
55	A. Jurado-Román; J. Abellán-Huerta; J. A. Requena; I. Sánchez-Pérez; M. T. López-Lluva; R. Maseda-Uriza; J. Piqueras-Flores; P. Pérez-Díaz; R. Frías-García; F. Lozano-Ruíz-Poveda	2019	Comparison of Clinical Outcomes Between Very Long Stents and Overlapping Stents for the Treatment of Diffuse Coronary Disease in Real Clinical Practice	Bare metal stents included in intervention group.
56	E. Kandzari David; S. Kini Annapoorna; D. Karmpaliotis; W. Moses Jeffrey; E. Tummala Pradyumna; J. A. Grantham; C. Orr; W. Lombardi; J. Nicholson William; J. Lembo Nicholas; J. Popma Jeffrey; J. Wang; C. Larracas; R. Rutledge David	2015	Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization	Not a key subgroup in scope.
57	D. E. Kandzari; A. J. Kirtane; S. Windecker; A. Latib; E. Kedhi; R. Mehran; M. J. Price; A. Abizaid; D. I. Simon; S. G. Worthley; A. Zaman; J. W. Choi; R. Caputo; M. Kanitkar; B. McLaurin; S. Potluri; T. Smith; D. Spriggs; T. Tolleson;	2020	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients	Duplicate.

#	Reference	Year	Title	Reason for exclusion
	T. Nazif; M. Parke; L. C. Lee; T. H. Lung; G. W. Stone			
58	S. H. Kang; W. Y. Chung; J. M. Lee; J. J. Park; C. H. Yoon; J. W. Suh; Y. S. Cho; J. H. Doh; J. M. Cho; J. W. Bae; T. J. Youn; I. H. Chae	2017	Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial	Less than 1 year follow-up.
59	P. P. Karjalainen; V. Varho; W. Nammas; J. Mikkelsson; M. Pietilä; A. Ylitalo; J. K. E. Airaksinen; J. Sia; K. Nyman; F. Biancari	2015	Early Neointimal Coverage and Vasodilator Response Following Biodegradable Polymer Sirolimus-Eluting vs. Durable Polymer Zotarolimus-Eluting Stents in Patients With Acute Coronary Syndrome–HATTRICK-OCT Trial–	Less than 1 year follow-up.
60	D. Karmpaliotis; R. Stoler; S. Walsh; S. El-Jack; S. Potluri; J. Moses; K. Oldroyd; A. Banning; M. Webster; A. Zaman; W. Wu; M. Ahmed; P. Underwood; D. Allocco	2022	Safety and efficacy of Everolimus-Eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study	Duplicate.
61	D. J. Kereiakes; I. Meredith; S. Windecker; A. Kabour; A. Bouchard; A. Kini; L. Janssens; M. Foster; R. Stoler; T. Stuckey; W. Batchelor; T. Christen; D. Allocco; K. Dawkins	2016	Late clinical outcomes after bioresorbable or permanent polymer everolimuseluting stents: 2-year results from the evolve II randomized trial	Abstract of included RCT.
62	Y. H. Kim; A.-Y. Her; M. H. Jeong; B.-K. Kim; S.-J. Hong; D.-H. Shin; J.-S. Kim; Y.-G. Ko; D. Choi; M.-K. Hong; Y. Jang	2019	Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR	Not a key subgroup in scope.
63	Y. Kim; S. S. Oh; M. H. Jeong; Y. Ahn; J. H. Kim; Y. J. Hong; D. S. Sim; M. C. Kim; H.-S. Kim; K. H. Yun; S. K. Oh; C. J. Kim; M. C. Cho	2019	Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR)	Less than 1 year follow-up.
64	A. J. Kirtane; R. Stoler; R. Feldman; F.-J. Neumann; L. Boutis; N. Tahirkheli; R. Toelg; I. Othman; B. Stein; J. W. Choi; S. Windecker; R. W. Yeh; H. L. Dauerman; M. J. Price; P. Underwood; D. Allocco; I. Meredith; D. J. Kereiakes	2021	Primary Results of the EVOLVE Short DAPT Study	Duplicate.

#	Reference	Year	Title	Reason for exclusion
65	O. Kobo; M. Saada; P. Laanmets; D. Karageorgiev; H. Routledge; J. Crowley; P. Baello; J. B. Requena; F. Spano; L. Perez; J. M. Jimenez Mazuecos; M. A. Mamas; A. Roguin	2022	Impact of peripheral artery disease on prognosis after percutaneous coronary intervention: Outcomes from the multicenter prospective e-ULTIMASTER registry	Objective/outcomes of study not relevant to decision problem.
66	O. Kobo; M. Saada; C. von Birgelen; P. A. L. Tonino; A. Iniguez-Romo; O. Frobert; M. Halabi; R. M. Oemrawsingh; J. Polad; A. J. J. Ijsselmuiden; M. Roffi; A. Aminian; M. A. Mamas; A. Roguin	2023	Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry	Objective/outcomes of study not relevant to decision problem.
67	R. Kornowski; K. Orvin; B. Merkely; G. Richardt; A. Colombo; J. L. Bonnet; W. Wijns	2016	Treatment of bifurcation lesions with a thin-strut DES with bioresorbable polymer: Three-year clinical outcomes of the CENTURY II trial	Abstract of included RCT.
68	K. Kozuma; Y. Kinoshita; H. Hioki; M. Nanasato; Y. Ito; J. Yamaguchi; N. Shiode; K. Hibi; K. Tanabe; J. Ako	2020	1-Year safety of 3-month dual antiplatelet therapy followed by aspirin or P2Y12 receptor inhibitor monotherapy using a bioabsorbable polymer sirolimus-eluting stent	Objective/outcomes of study not relevant to decision problem.
69	F. Krackhardt; V. Kočka; M. W. Waliszewski; A. Utech; M. Lustermann; M. Hudec; M. Studenčan; M. Schwefer; J. Yu; M. H. Jeong; T. Ahn; W. A. Wan Ahmad; M. Boxberger; A. Schneider; M. Leschke	2017	Polymer-free sirolimus-eluting stents in a large-scale all-comers population	Less than 1 year follow-up.
70	F. Krackhardt; M. Waliszewski; V. Kočka; P. Toušek; B. Janek; M. Hudec; F. Lozano; K. G.-S. Roman; B. G. del Blanco; J. Mauri; T. M. Heang; T. H. Ahn; M. H. Jeong; D. Herberger; V. Tomulic; G. Levy; L. Sebagh; J. Rischner; M. Pansieri	2020	Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease	Objective/outcomes of study not relevant to decision problem.
71	E. Kretov; I. Naryshkin; V. Baystrukov; I. Grazhdankin; A. Prokhorikhin; D. Zubarev; A. Biryukov; V. Verin; A. Boykov; D. Malaev; E. Pokushalov; A. Romanov; M. W. Bergmann	2018	Three-months optical coherence tomography analysis of a biodegradable polymer, sirolimus-eluting stent	Less than 1 year follow-up.
72	M. W. Krucoff; P. Urban; J.-F. Tanguay; T. McAndrew; Y. Zhang; S. V. Rao; M.-C. Morice; M. J. Price; D. J. Cohen; M. Abdel-Wahab; S. R. Mehta; B. Faurie; B. McLaurin; C. Diaz; H.-P. Stoll; S. Pocock; M. B. Leon	2020	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents	Comparator out of scope.

#	Reference	Year	Title	Reason for exclusion
73	A. Latib; L. Ferri; A. Ielasi; C. Godino; A. Chieffo; V. Magni; G. Bassanelli; A. S. P. Sharp; R. Gerber; I. Michev; M. Carlino; F. Airoldi; G. M. Sangiorgi; M. Montorfano; A. Colombo	2009	Clinical outcomes after unrestricted implantation of everolimus-eluting stents	Less than 1 year follow-up.
74	S. W. L. Lee; F. C. C. Tam; K. K. W. Chan; S. C. C. Lam; S.-L. Kong; C. P. Shea; M. K. L. Wong; A. Y. T. Wong; A. S. Y. Yung; L.-W. Zhang; Y.-M. Lam; G. S. Mintz; R. A. Costa; H.-P. Stoll; A. Maehara	2018	Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study	Less than 1 year follow-up.
75	T. Lefevre; M. Haude; F.-J. Neumann; K. Stangl; C. Skurk; T. Slagboom; M. Sabate; J. Goicolea; P. Barragan; S. Cook; J.-C. Macia; S. Windecker	2018	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial	RCT not powered to assess key clinical outcomes at a minimum of one year.
76	T. Lefèvre; M. Haude; F. J. Neumann; K. Stangl; C. Skurk; T. Slagboom; M. Sabaté; J. Goicolea; P. Barragan; S. Cook; J. C. Macia; S. Windecker	2018	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial	Duplicate.
77	Y. Levi; O. Kobo; M. Halabi; I. Al Haddad; B. Chevalier; J. Polad; P. Laanmets; A. Witkowski; J. Monsegu; A. R. Iniguez; M. A. Mamas; A. Roguin	2023	Treatment of Ostial Right Coronary Artery Narrowings: Outcomes From the Multicenter Prospective e-ULTIMASTER Registry	Objective/outcomes of study not relevant to decision problem.
78	C. Li; Y. Yang; Y. Han; D. Song; J. Xu; C. Guan; R. Gao; H. M. Garcia-Garcia; R. Waksman; B. Xu	2020	Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial	Less than 1 year follow-up.
79	X. T. Li; H. Sun; D. P. Zhang; L. Xu; Z. H. Ni; K. Xia; Y. Liu; Y. H. Chi; J. F. He; W. M. Li; H. S. Wang; L. F. Wang; X. C. Yang	2014	Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: Comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents	Non-randomised study, comparator device not in scope.
80	A. Loch; J. P. Bewersdorf; R. S. Veeriah	2017	Early and aggressive ISR with a polymer- and carrier-free drug-coated stent system	Less than 1 year follow-up.
81	J. A. Mailey; M. Ahmed; M. Hogg; C. Cosgrove; J. C. Murphy; A. H. McNeice; J. C. Spratt; M. S. Spence; S. J. Walsh	2021	Initial Experiences of Percutaneous Coronary Intervention Using a New-Generation Everolimus-Eluting Stent Platform	Less than 1 year follow-up.
82	A. S. Mahmood Zuhdi; F. Krackhardt; M. W. Waliszewski; M. D. Ismail; M. Boxberger; W. A. Wan Ahmad	2018	Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
83	N. Mankerious; R. Hemetsberger; H. Traboulsi; R. Toelg; M. Abdel-Wahab; G. Richardt; A. Allali	2021	Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy	Subgroup not in scope.
84	S. Mansour; G. Guilbert-Vandal; M. J. Bertrand; R. Kouz; L. M. Stevens; N. Noiseux; A. Kokis; F. Gobeil	2013	Safety and efficacy of a novel drug-eluting stent with a bioresorbable polymer in a real life cohort	Abstract (does not meet criteria for inclusion).
85	I. B. A. Menown; M. A. Mamas; J. M. Cotton; D. Hildick-Smith; F. R. Eberli; G. Leibundgut; D. Tresukosol; C. Macaya; S. Copt; S. Sadozai Slama; H.-P. Stoll	2020	First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha TM registry	Less than 1 year follow-up.
86	I. T. Meredith; S. Verheye; C. L. Dubois; J. Dens; J. Fajadet; D. Carrie; S. Walsh; K. G. Oldroyd; O. Varenne; S. El-Jack; R. Moreno; A. A. Joshi; D. J. Allocco; K. D. Dawkins	2012	Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent	Less than 1 year follow-up.
87	I. T. Meredith; S. Verheye; N. J. Weissman; P. Barragan; D. Scott; M. V. Chávarri; N. E. J. West; H. Kelbæk; R. Whitbourn; D. L. Walters; J. Kubica; L. Thuesen; M. Masotti; A. Banning; I. Sjögren; R. H. Stables; D. J. Allocco; K. D. Dawkins	2013	Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent	Primary outcome not a key clinical outcome.
88	M. O. Mohamed; J. Polad; D. Hildick-Smith; O. Bizeau; R. K. Baisebenov; M. Roffi; A. Iniguez-Romo; B. Chevalier; C. von Birgelen; A. Roguin; A. Aminian; M. Angioi; M. A. Mamas	2021	Impact of coronary lesion complexity in percutaneous coronary intervention: One-year outcomes from the large, multicentre e-Ultimaster registry	Objective/outcomes of study not relevant to decision problem.
89	M. R. Monjur; C. F. Said; P. Bamford; M. Parkinson; R. Szirt; T. Ford	2020	Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis	Relevant primary trials already considered for inclusion separately.
90	J. Moreu; R. Moreno-Gómez; A. Perez de Prado; B. García del Blanco; R. Trillo; E. Pinar; E. Molina; J. Zueco; A. Merchán; J. F. Díaz-Fernández; I. J. Amat-Santos	2019	First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial	Duplicate.
91	Y. Morino; D. Terashita; H. Otake; T. Kikuchi; T. Fusazaki; N. Kuriyama; T. Suzuki; Y. Ito; K. Hibi; H. Tanaka; S. Ishihara; T. Kataoka; T. Morita; Y. Otsuka; T. Hayashi; K. Tanabe; T. Shinke	2019	Early vascular responses to everolimus-eluting cobalt–chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study)	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
92	C. Musto; L. Paolucci; C. A. Pivato; L. Testa; A. Pacchioni; C. Briguori; G. Esposito; R. Piccolo; L. Lucisano; L. De Luca; F. Conrotto; J. Sanz-Sanchez; V. Cesario; F. De Felice; A. C. Latini; D. Regazzoli; G. Sardella; C. Indolfi; B. Reimers; G. Condorelli; G. Stefanini	2023	One-Month Dual Antiplatelet Therapy in Patients With Chronic and Acute Coronary Syndromes Treated With Bioresorbable Polymer Everolimus-Eluting Stents	Comparison between populations not relevant to decision problem.
93	A. A. B. Nuruddin; W. A. W. Ahmad; M. Waliszewski; T. M. Heang; L. H. Bang; A. K. M. Yusof; I. Z. Abidin; A. S. Zuhdi; F. Krackhardt	2021	Impact of Coronary Stent Architecture on Clinical Outcomes: Do Minor Changes in Stent Architecture Really Matter?	Comparison of device generations.
94	Y. Onuma; S. Tanimoto; P. Ruygrok; J. Neuzner; J. J. Piek; A. Seth; J. J. Schofer; G. Richardt; M. Wiemer; D. Carrié; L. Thuesen; C. Dorange; K. Miquel-Hebert; S. Veldhof; P. W. Serruys	2010	Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two-year angiographic and three-year clinical results from the SPIRIT II study	Non-comparative study with older generation device.
95	J. Y. Park; S.-W. Rha; Y.-K. Noh; B. G. Choi; J. Y. Hong; J.-W. Choi; S. K. Ryu; S.-H. Park; Y. H. Kim; M. H. Jeong	2021	Real-World Three-Year Clinical Outcomes of Biolimus-Eluting Stents versus Other Contemporary Drug-Eluting Stents in Patients with Acute Myocardial Infarction Patients: Data from the Korea Acute Myocardial Infarction Registry (KAMIR)	Comparing groups of stents with out of scope stents included in groups, results not reported per individual stent.
96	K. W. Park; J. M. Lee; S. H. Kang; H. S. Ahn; H. M. Yang; H. Y. Lee; H. J. Kang; B. K. Koo; J. Cho; H. C. Gwon; S. Y. Lee; I. H. Chae; T. J. Youn; J. K. Chae; K. R. Han; C. W. Yu; H. S. Kim	2013	Safety and efficacy of second-generation everolimus-eluting Xience v Stents versus zotarolimus-eluting resolute stents in real-world practice: Patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries	Out of scope comparator.
97	K. P. Patel; A. J. Lansky; H. Kelbaek; B. Xu; N. van Royen; T. W. Johnson; R. Anderson; W. Wijns; A. Baumbach	2024	Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)	Out of scope subgroup of included RCT.
98	S. Patra; R. N. Chakraborty; A. Pande; S. Banerjee; M. Jena; P. C. Mandal; S. K. De; A. Khan; S. S. Das; D. Ghosh; R. Nag	2017	Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis	Intervention not in scope.
99	S. V. Patted; A. S. Patted; P. K. Turiya; A. S. Thakkar	2018	Clinical Outcomes of World's Thinnest (50 mumr) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients	Less than 1 year follow-up.
100	R. Piccolo; G. G. Stefanini; A. Franzone; E. Spitzer; S. Blöchlinger; D. Heg; P. Jüni; S. Windecker	2015	Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents	Systematic review, intervention is out of scope stent.

#	Reference	Year	Title	Reason for exclusion
101	T. Pilgrim; O. Muller; D. Heg; M. Roffi; D. J. Kurz; I. Moarof; D. Weilenmann; C. Kaiser; M. Tapponnier; S. Losdat; E. Eeckhout; M. Valgimigli; P. Jüni; S. Windecker; J. F. Iglesias	2021	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial	Duplicate.
102	T. Pilgrim; M. Rothenbühler; G. C. Siontis; D. E. Kandzari; J. F. Iglesias; M. Asami; T. Lefèvre; R. Piccolo; J. Koolen; S. Saito; T. Slagboom; O. Muller; R. Waksman; S. Windecker	2021	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials	Relevant primary trials already considered for inclusion separately.
103	C. A. Pivato; B. Reimers; L. Testa; A. Pacchioni; C. Briguori; C. Musto; G. Esposito; R. Piccolo; L. Lucisano; L. De Luca; F. Conrotto; A. De Marco; A. Franzone; P. Presbitero; G. Ferrante; G. Condorelli; V. Paradies; G. Sardella; C. Indolfi; G. Condorelli; G. G. Stefanini	2022	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients	Duplicate.
104	E. H. Ploumen; R. A. Buiten; P. Zocca; C. J. M. Doggen; G. A. J. Jessurun; C. E. Schotborgh; A. Roguin; P. W. Danse; E. Benit; A. Aminian; R. L. Anthonio; S. Somi; G. C. M. Linssen; M. Hartmann; M. M. Kok; C. von Birgelen	2021	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial	Out of scope subgroup of included RCT.
105	E. H. Ploumen; T. H. Pinxterhuis; R. A. Buiten; P. Zocca; P. W. Danse; C. E. Schotborgh; M. Scholte; R. Gin; S. Somi; K. G. van Houwelingen; M. G. Stoel; H. A. F. de Man; M. Hartmann; G. C. M. Linssen; L. C. van der Heijden; M. M. Kok; C. J. M. Doggen; C. von Birgelen	2022	Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-Comers	Duplicate.
106	W. Postma; E. Fabris; M. Van der Ent; R. Hermanides; P. Buszman; C. Von Birgelen C; S. Cook; H. Wedel; G. De Luca; R. Delewi; F. Zijlstra; E. Kedhi	2020	Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial	Less than 1 year follow-up.
107	R. Puri; I. Otaegui; M. Sabaté; A. Serra-Peñaranda; M. Puigfel; A. Perez de Prado; L. Nombela-Franco; J. M. de la Torre Hernandez; R. Ortas Nadal; A. Iniguez-Romo; et al.	2018	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: the ANCHOR study	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
108	R. Puri; I. Otaegui; M. Sabaté; A. Serra-Peñaranda; M. Puigfel; A. Perez de Prado; L. Nombela-Franco; J. M. de la Torre Hernandez; R. Ortas Nadal; A. Iniguez-Romo; G. Jiménez; F. Fernandez-Vazquez; C. Cuellas-Ramon; N. Gonzalo; V. Alfonso Jiménez Diaz; L. Duocastella; M. Molina; M. Amoros; I. Perez; A. Barria Perez; E. Pelletier Beaumont; S. J. Nicholls; B. Garcia del Blanco; J. Rodés-Cabau	2018	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study	Duplicate.
109	J. Qian; B. Xu; A. J. Lansky; Y. J. Yang; S. B. Qiao; Y. J. Wu; J. Chen; F. H. Hu; W. X. Yang; G. S. Mintz; M. B. Leon; R. L. Gao	2012	First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: Results of the first in man FIREHAWK trial	Less than 1 year follow-up.
110	T. Roleder; E. Kedhi; B. Berta; P. Gasior; W. Wanha; M. Roleder; J. Fluder; G. Smolka; A. Ochala; W. Wojakowski	2019	Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study	Less than 1 year follow-up.
111	A. Roguin; D. E. Kandzari; E. Marcusohn; J. J. Koolen; G. Doros; J. M. Massaro; H. M. Garcia-Garcia; J. Bennett; E. G. Gharib; D. E. Cutlip; R. Waksman	2018	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients	Out of scope subgroup of included RCT.
112	M. Saada; O. Kobo; F. Kauer; O. Sakhov; P. Laanmets; R. Abhaichand; I. Lozano; J. Crowley; G. S. Wander; M. A. Mamas; A. Roguin	2022	Prognosis of PCI in the Older Adult Population: Outcomes From the Multicenter Prospective e-ULTIMASTER Registry	Objective/outcomes of study not relevant to decision problem.
113	M. Saada; O. Kobo; J. Polad; M. Halabi; I. J. AJJ; Á. Puentes; J. Monségu; D. Austin; R. K. Baisebenov; F. Spanó; A. Roguin	2022	Prognosis of PCI in AMI setting in the elderly population: Outcomes from the multicenter prospective e-ULTIMASTER registry	Objective/outcomes of study not relevant to decision problem.
114	Y. Saito; W. Wijns; A. Baumbach; B. Xu; H. Kelbaek; M. Zheng; M.-A. Morel; R. Anderson; V. Schachinger; A. Lansky	2022	Differential impact of abluminal groove-filled biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent on and off dual antiplatelet therapy	Out of scope subgroup of included RCT.
115	S. Saito; K. Ando; Y. Ito; T. Tobaru; J. Yajima; T. Kimura; K. Kadota	2019	Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study	Longer term results available.

#	Reference	Year	Title	Reason for exclusion
116	S. Saito; N. Hagiwara; A. Seki; K. Igarashi; T. Muramatsu; J. Yajima; H. Yokoi; M. Nakamura; K. Fujii; T. Isshiki; G. W. Stone; P. S. Teirstein; I. T. Meredith; D. J. Allocco; K. D. Dawkins	2014	Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents	Out of scope subgroup of included RCT.
117	Y. Saito; A. Baumbach; W. Wijns; B. Xu; H. Kelbaek; M. Zheng; M.-A. Morel; R. Anderson; V. Schachinger; A. Lansky	2020	Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent	Relevant data already included in main trial publication.
118	G. Sarno; B. Lagerqvist; G. Olivecrona; C. Varenhorst; M. Danielewicz; K. Hambraeus; D. Lindholm; T. Råmunddal; N. Witt; S. James	2017	Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)	Duplicate.
119	G. G. Secco; A. Mattesini; R. Fattori; R. Parisi; F. Castriota; M. Vercellino; G. Dall'Ara; L. Uguccioni; L. Marinucci; G. De Luca; P. N. Marino; G. Pistis; C. Di Mario	2016	Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography	Less than 1 year follow-up.
120	A. Seth; R. Costa; U. Kaul; G. Wander; A. Mullasari; C. Nanjappa; P. Heggunje-Shetty	2016	Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt–chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial	Longer term results available.
121	A. Seth; G. Singh; M. Sankardas; M. Nanjappa; P. Heggunje; T. Alexander; S. Hardas; M. Kalaricka; S. Abraham; S. Vijan; R. Kumar; A. Abizaid	2017	Three-year clinical outcomes of biomime sirolimus-eluting coronary stent system with a biodegradable polymer in coronary artery disease patients: A long-term follow-up of the merit-2 study	Abstract of single-arm study.
122	A. Sethi; V. Kodumuri; V. Prasad; J. Kassotis	2021	Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable polymer everolimus-eluting stent for percutaneous coronary intervention: a meta-analysis of randomized trials	Relevant primary trials already considered for inclusion separately.
123	R. Shetty; J. Prajapati; U. Pai; K. Shetty	2016	Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study	Less than 1 year follow-up.
124	S. Silber; S. Windecker; P. Vranckx; P. W. Serruys	2011	Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial	Intervention not in scope.

#	Reference	Year	Title	Reason for exclusion
125	G. G. Stefanini; P. W. Serruys; S. Silber; A. A. Khattab; R. J. van Geuns; G. Richardt; P. E. Buszman; H. Kelbæk; A. J. van Boven; S. H. Hofma; A. Linke; V. Klauss; W. Wijns; C. Macaya; P. Garot; C. Di Mario; G. Manoharan; R. Kornowski; T. Ischinger; A. L. Bartorelli; P. Gobbens; S. Windecker	2011	The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention)	Intervention not in scope.
126	S. Stojkovic; A. N. Neskovic; Z. Mehmedbegovic; S. Kafedzic; M. Ostojic; M. Nedeljkovic; D. Orlic; B. Ilisic; I. Ilic; A. Aleksic; M. Cerovic; I. Nikolajevic; A. Vlahovic-Stipac; Z. Stajic; B. Putnikovic; M. Hamilos	2015	Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease	Objective/outcomes of study not relevant to decision problem.
127	Y. Tadano; J.-I. Kotani; Y. Kashima; D. Hachinohe; T. Watanabe; T. Sugie; U. Kaneko; K. Kobayashi; D. Kanno; T. Fujita	2019	Predictors of clinical outcomes after coronary implantation of bioresorbable polymer sirolimus-eluting Ultimaster stents in all-comers: A report of 1,727 cases	Objective/outcomes of study not relevant to decision problem.
128	N. Taglieri; G. Bruno Antonio; G. Ghetti; C. Marrozzini; F. Saia; N. Galié; T. Palmerini	2020	Target Lesion Failure With Current Drug-Eluting Stents	Duplicate.
129	G. Tarantini; F. Cardaioli; G. De Iaco; B. Tuccillo; M. C. De Angelis; C. Mauro; M. Boccalatte; A. Trivisonno; F. Ribichini; G. Vadalà; G. Caramanno; M. Caruso; M. Lombardi; D. Fischetti; A. Danesi; L. Abbracciavento; G. Lorenzoni; D. Gregori; A. Panza; L. Nai Fovino; G. Esposito	2024	A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry)	Duplicate.
130	K. Teeuwen; E. M. Spoormans; J. Bennett; C. Dubois; W. Desmet; G. J. Ughi; A. Belmans; J. C. Kelder; J. G. P. Tijssen; P. Agostoni; M. J. Suttorp; T. Adriaenssens	2017	Optical coherence tomography findings: insights from the “randomised multicentre trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions” (PRISON IV) trial	Less than 1 year follow-up.
131	K. Teeuwen; R. J. van der Schaaf; T. Adriaenssens; J. J. Koolen; P. C. Smits; J. P. Henriques; P. H. Vermeersch; R. M. Tjon Joe Gin; B. E. Schölzel; J. C. Kelder; J. G. Tijssen; P. Agostoni; M. J. Suttorp	2017	Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
132	P. Teirstein; G. W. Stone; I. T. Meredith; A. C. Rabinowitz; V. J. Pompili; T. C. Lee; L. A. Cannon; D. J. Kereiakes; M. Mooney; D. Carrie; S. Saito; D. J. Allocco; K. D. Dawkins	2015	Final five-year outcomes following implantation of the promus element platinum chromium everolimus-eluting stent in de novo coronary artery lesions in small vessels (SV) and long lesions (LL): Results of the PLATINUM small vessel and long lesion trials	Abstract of included RCT.
133	R. Toelg; T. Slagboom; J. Waltenberger; T. Lefèvre; S. Saito; D. E. Kandzari; J. Koolen; G. Richardt	2021	Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent	Relevant primary trials already considered for inclusion separately.
134	T. Tsujimura; T. Ishihara; O. Iida; Y. Hata; T. Toyoshima; N. Higashino; N. Kurata; M. Asai; M. Masuda; S. Okamoto	2021	Arterial Healing 10 Months After Implantation of an Ultrathin-Strut, Biodegradable-Polymer, Sirolimus-Eluting Stent—An Angioscopic Study—	Less than 1 year follow-up.
135	E. Valero; L. Consuegra-Sanchez; G. Minana; S. Garcia-Blas; J. C. Rodriguez; P. Moyano; J. Sanchis; J. Nunez	2018	Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions	Less than 1 year follow-up.
136	C. von Birgelen; M. W. Basalus; K. Tandjung; K. G. van Houwelingen; M. G. Stoel; J. H. Louwerenburg; G. C. Linssen; S. A. Saïd; M. A. Kleijne; H. Sen; M. M. Löwik; J. van der Palen; P. M. Verhorst; F. H. de Man	2012	A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial	Duplicate.
137	C. von Birgelen; M. M. Kok; L. C. van der Heijden; P. W. Danse; C. E. Schotborgh; M. Scholte; R. Gin; S. Somi; K. G. van Houwelingen; M. G. Stoel; F. de Man; J. H. W. Louwerenburg; M. Hartmann; P. Zocca; G. C. M. Linssen; J. van der Palen; C. J. M. Doggen; M. M. Löwik	2016	Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial	Duplicate.
138	C. von Birgelen; H. Sen; M. K. Lam; P. W. Danse; G. A. Jessurun; R. W. Hautvast; G. K. van Houwelingen; A. R. Schramm; R. M. Gin; J. W. Louwerenburg; F. H. de Man; M. G. Stoel; M. M. Löwik; G. C. Linssen; S. A. Saïd; M. B. Nienhuis; P. M. Verhorst; M. W. Basalus; C. J. Doggen; K. Tandjung	2014	Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial	Duplicate.
139	R. Waksman; E. Shlofmitz; S. Windecker; J. J. Koolen; S. Saito; D. Kandzari; P. Kolm; M. J. Lipinski; R. Torguson	2019	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus	Relevant primary trials already considered for inclusion separately.

#	Reference	Year	Title	Reason for exclusion
140	J. Waltenberger; J. Brachmann; J. van der Heyden; G. Richardt; O. Fröbert; M. Seige; A. Erglis; W. Dewilde; M. Winkens; C. Hegeler-Molkewehrum; N. Klein; S. Hoffmann	2016	Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry	Longer term results available.
141	T. Williams; A. Mittal; D. Karageorgiev; A. Iniguez Romo; A. Aminian; J. Fernandez Portalese; E. Kharrat; J. A. Gomez-Hospital; D. Firman; R. Trillo Nouche; D. Hildick-Smith	2022	Complete revascularization optimizes patient outcomes in multivessel coronary artery disease: Data from the e-Ultimaster registry	Objective/outcomes of study not relevant to decision problem.
142	J. Wohrle; S. Markovic; W. Rottbauer; T. Muramatsu; K. Kadota; N. Vazquez-Gonzalez; J. Odenstedt; A. Serra; D. Antoniucci; O. Varenne; S. Saito; W. Wijns	2016	Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial	Out of scope subgroup of included RCT.
143	S. G. Worthley; A. Abizaid; A. J. Kirtane; D. I. Simon; S. Windecker; S. Brar; I. T. Meredith; S. Shetty; A. Sinhal; A. P. Almonacid; D. Chamie; A. Maehara; G. W. Stone	2017	First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study	Less than 1 year follow-up.
144	B. Xu; R. L. Gao; R. Y. Zhang; H. C. Wang; Z. Q. Li; Y. J. Yang; C. S. Ma; Y. L. Han; A. J. Lansky; Y. Huo; W. Li; M. B. Leon	2013	Efficacy and safety of FIREHAWK abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: Nine-month angiographic and one-year clinical results from TARGET I trial long cohort	Less than 1 year follow-up.
145	W. Yeh Robert; S. Silber; L. Chen; S. Chen; S. Hiremath; F.-J. Neumann; S. Qiao; S. Saito; B. Xu; Y. Yang; L. Mauri	2017	5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent	Device out of scope.
146	R. W. Yeh; S. Silber; L. Chen; S. Chen; S. Hiremath; F. J. Neumann; S. Qiao; S. Saito; B. Xu; Y. Yang; L. Mauri	2017	5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program	Duplicate.
147	C. Zanchin; Y. Ueki; T. Zanchin; J. Häner; T. Otsuka; S. Stortecky; C. Koskinas Konstantinos; C. M. Siontis George; F. Praz; A. Moschovitis; L. Hunziker; M. Valgimigli; T. Pilgrim; D. Heg; S. Windecker; L. Räber	2019	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice	Duplicate.
148	Y. J. Zhang; W. Wu; D. R. Pan; B. Xu; J. Kan; Y. X. Chen; S. Pang; W. You; J. J. Zhang; F. Ye; S. L. Chen	2015	Feasibility of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent in patients with complex anatomical and clinical scenarios	Less than 1 year follow-up.
149	C. Zivelonghi; J. P. van Kuijk; V. Nijenhuis; E. Poletti; M. J. Suttorp; J. A. S. van der	2018	First report of the use of long-tapered sirolimus-eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm	Less than 1 year follow-up.

#	Reference	Year	Title	Reason for exclusion
	Heyden; F. D. Eefting; B. J. Rensing; J. M. ten Berg; L. Azzalini; F. S. van den Brink; F. Ribichini; A. Colombo; J. P. S. Henriques; P. Agostoni			
150	C. Zivelonghi; K. Teeuwen; P. Agostoni; R. J. van der Schaaf; F. Ribichini; T. Adriaenssens; J. C. Kelder; J. G. P. Tijssen; J. P. S. Henriques; M. J. Suttorp	2018	Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial	Less than 1 year follow-up.
151	P. Zocca; M. M. Kok; K. Tandjung; P. W. Danse; G. A. J. Jessurun; R. W. M. Hautvast; K. G. van Houwelingen; M. G. Stoel; A. R. Schramm; R. M. Tjon Joe Gin; F. de Man; M. Hartmann; J. H. W. Louwerenburg; G. C. M. Linssen; M. M. Löwik; C. J. M. Doggen; C. von Birgelen	2018	5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial	Duplicate.